Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depression disorder for use by adult specialist mental health services in New Zealand

  • Ben Beaglehole, Paul Glue, Mike Clarke, Richard Porter
  • Journal:
    BJPsych Open / Volume 9 / Issue 6 / November 2023
    Published online by Cambridge University Press:
    13 October 2023, e191
    • Article
      • You have access
      • Open access
    • PDF
    • HTML
    • Export citation
  • Background

    The evidence base for racemic ketamine treatment for treatment-resistant major depressive disorder (TRD) continues to expand, but there are major challenges translating this evidence base into routine clinical care.

    Aim

    To prepare guidelines for ketamine treatment of TRD that are suitable for routine use by publicly funded specialist mental health services.

    Method

    We consulted with senior leadership, clinical pharmacy, psychiatrists, nursing, service users and Māori mental health workers on issues relating to ketamine treatment. We prepared treatment guidelines taking the evidence base for ketamine treatment and the consultation into account.

    Results

    Ketamine treatment guidance is reported. This offers two treatment pathways, including a test of ketamine responsiveness with intramuscular ketamine and the dominant use of oral ketamine for a 3-month course to maximise the opportunity for the short-term benefits of ketamine to accumulate.

    Conclusions

    We have responded to the challenges of translating the evidence base for ketamine treatment into a form suitable for routine care.

  • Oral ketamine premedication in children (placebo controlled double-blind study)

  • S. Şekerci, A. Dönmez, Y. Ateş, F. Ökten
  • Journal:
    European Journal of Anaesthesiology / Volume 13 / Issue 6 / November 1996
    Published online by Cambridge University Press:
    04 August 2006, pp. 606-611
    Print publication:
    November 1996

  • Ketamine 3–6 mg kg−1 given by mouth to paediatric patients for anaesthetic premedication was evaluated. Forty-three children, ages 2–9 years were randomly allocated to receive either ketamine (3 or 6mg kg−1) or placebo (cola 0.2 mL kg−1). Oral use of ketamine made separation from the families easier, gave an increased level of sedation, made acceptance of mask application easier and improved the emotional state in the recovery phase. These improvements were present with ketamine 3mg kg−1 and 6mg kg−1 in comparison with the placebo. We conclude that 3mg kg−1 ketamine given by mouth to premedicate paediatric patients is as effective as 6mg kg−1 but has a decreased incidence of side effects such as nystagmus and vomiting.